Health

Ubicom Holdings Japan helped gynaecological imaging software developer Illumigyn take its total funding to $33m while Optum took part in a $30m round for health payment technology provider Medallion.

The wearable glucose monitor developer’s nine-figure series B round included M Ventures, Hikma Ventures, Axa Investment Management, Ascencia, Hikm Taisho, Cirrus Logic and EOFlow.

Alphabet returned to reinvest in the epigenetics diagnostics technology developer through a series D round that took its total funding to about $145m.

Bristol Myers Squibb was among the participants in cellular therapy developer Clade Therapeutics' series A round, with the proceeds to go to platform development.

Cancer drug developer Parthenon Therapeutics secured the funding in a series A round co-led by Pfizer Ventures and Taiho Ventures.

Cox Enterprises invested in digital media company Axios at a $430m valuation while Bristol Myers Squibb helped enzyme drug developer Nitrase Therapeutics boost its series A round to $45m.

Gilead and BeiGene participated in a round for the immuno-oncology therapeutics developer in a round that came seven months after it raised $43m.

Bayer’s Marianne De Backer spoke with GCV’s James Mawson on the latest in the biotech scene.

Corporate-backed financial remittance network operator Lightnet netted over $48m while Callaway Golf Company invested $30m in indoor golfing chain Five Iron Golf.